Cancer stocks grow

Article Abstract:

In 2003 Australia's cancer-research companies had a good year buoyed by a combination of favorable news from the US about new drugs with encouraging results being developed and so share prices almost doubled in some small companies linked to cancer research. However, cancer research is a risky business but if two or three Australian companies are successful, it until is better than normal odds.

United States, Securities issued, listed, HEALTH SERVICES, Care and treatment, Health care industry, Securities, Cancer, Dosage and administration, Company securities

---

Medicare cuts an artery

Article Abstract:

The federal funding on two important areas of health care has been increasing rapidly. While the cost of Medicare rose by 12.8% in the September quarter, the Pharmaceutical Benefits Scheme involving subsidizing drugs increased by 12.6% in the same quarter. The evaluation of the Medicare safety net scheme is also discussed.

Government expenditures, Commodity & service prices, Prices and rates, Medicare, Company pricing policy, Government finance

---

The next code crackers

Article Abstract:

Large pharmaceutical makers are looking for small biotech firms to do the research that can lead to new drugs. The activities of various Australian companies are discussed.

Product development, Research, Pharmaceutical industry, Brief Article, Biotechnology

Similar abstracts:

• Abstracts: Paper & forest products industry
• Abstracts: Pharmacy services industry. Medical services industry
• Abstracts: Grocery store industry. part 4
• Abstracts: Bracks' chronic problem. Bracks must tame the union tiger. Victoria must hold its nerve
• Abstracts: Secondary markets stir. Picking shock-proof stocks for scary times. The future is ours--maybe

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.